Vaxart to Participate in BTIG Infectious Disease Day 2026

Vaxart (OTCQX: VXRT), a clinical-stage biotech developing oral recombinant vaccines, announced participation in BTIG Infectious Disease Day 2026 on June 16, 2026.

Rhea-AI Summary

Vaxart (OTCQX: VXRT), a clinical-stage biotech developing oral recombinant vaccines, announced participation in BTIG Infectious Disease Day 2026 on June 16, 2026.

The virtual event will feature 1x1 meetings between Vaxart management and institutional investors arranged through BTIG representatives.

Argus Jun 9 session

-3.12% close to close Open Argus

Details

News Market Reaction – VXRT

In the Jun 9 session, VXRT declined 3.12%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement centers on Vaxart’s participation in BTIG Infectious Disease Day 2026 on June 16, ...

Analysis

This announcement centers on Vaxart’s participation in BTIG Infectious Disease Day 2026 on June 16, 2026, offering 1x1 meetings with institutional investors. In context, the company recently reported Q1 2026 revenue of $39.2 million and net income of $5.2 million, and has an effective $300,000,000 shelf and ATM capacity. Investors may monitor how such outreach supports interest in its BARDA-backed oral vaccine programs and upcoming data milestones.

Key Figures

Conference date: June 16, 2026 Meeting format: 1x1 meetings Event year: 2026

Conference date

June 16, 2026

BTIG Infectious Disease Day 2026 participation

Meeting format

1x1 meetings

BTIG Infectious Disease Day 2026

Event year

2026

BTIG Infectious Disease Day 2026 title

Historical Context

5 past events · Latest: Jun 08

5 events

1. Jun 08

   Proxy solicitation

   24h Move

   -5.4%

   Company urged votes for its six director nominees ahead of July 16 meeting.

2. Jun 01

   Definitive proxy filed

   24h Move

   -2.3%

   Filed definitive proxy and highlighted pipeline, funding, and leadership alignment.

3. May 19

   Preliminary proxy filed

   24h Move

   -1.6%

   Preliminary proxy and letter seeking support for current Board amid trial progress.

4. May 07

   Q1 2026 earnings

   24h Move

   -5.4%

   Reported Q1 revenue, net income, BARDA funding and extended cash runway.

5. May 01

   Investor event notice

   24h Move

   +0.0%

   Announced May 8 virtual stockholder fireside chat and Q1 2026 earnings timing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of the management team will participate in the BTIG Infectious Disease Day 2026 on June 16.

BTIG Infectious Disease Day 2026
Date: Tuesday, June 16, 2026
Format: 1x1 Meetings
Location: Virtual

Institutional Investors interested in meeting with Vaxart management should contact their BTIG representative.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact
Vaxart Media and Investor Relations:
FINN Partners
IR@vaxart.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Vaxart (OTCQX: VXRT) announcing about BTIG Infectious Disease Day 2026?

Vaxart announced its management will participate in BTIG Infectious Disease Day 2026 on June 16. The company plans virtual 1x1 meetings with institutional investors, which must be arranged through BTIG representatives.

When will Vaxart (VXRT) attend BTIG Infectious Disease Day 2026?

Vaxart will participate in BTIG Infectious Disease Day 2026 on Tuesday, June 16, 2026. According to Vaxart, the company’s management will hold virtual 1x1 meetings with interested institutional investors during the event.

What is the format of Vaxart’s participation at BTIG Infectious Disease Day 2026?

Vaxart’s participation will be in a virtual 1x1 meeting format with institutional investors. According to Vaxart, investors can request meetings with management through their BTIG representative for the June 16, 2026 event.

How can institutional investors meet Vaxart (VXRT) management during BTIG Infectious Disease Day 2026?

Institutional investors can request meetings with Vaxart management by contacting their BTIG representative. According to Vaxart, these meetings will take place as virtual 1x1 sessions on June 16, 2026 during the event.

What type of company is Vaxart (VXRT) presenting at BTIG Infectious Disease Day 2026?

Vaxart is a clinical-stage biotechnology company developing oral recombinant vaccines using a proprietary delivery platform. According to Vaxart, its management will highlight the business to institutional investors via virtual 1x1 meetings at the June 16, 2026 event.